Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Post by Valuehunter72on Jun 11, 2020 9:03pm
102 Views
Post# 31141281

What Order Did This Happen Attempt 2

What Order Did This Happen Attempt 2

Did Vaxil get approved for funding first, then decided to do the dilutive financing to come up with their half of the funds first?  Would it not be prudent to press this information first?  This would have given stock price a boost if investors knew half of trial costs could be funded by Canadian government right?  Then do your private placement.  Why punish existing shareholders and let your buddies load up on the cheap......I sure hope that is not the case.

https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/clntSmmry?clientOrgCorpNumber=366559&sMdKy=1591402431278

why does the link below say funding expected in current year?  It has been there for over two weeks?  If you go to the link listed above and click on the highlighted yes.....this window in the link below pops up.

https://imgur.com/a/y9in8Fm


Please communicate with your shareholders David and not just to the private placement participants that get to sign a NDA and be privy to more information.  Would this not be considered material as it appears Vaxil has been accepted for funding in the strategic innovation fund?

<< Previous
Bullboard Posts
Next >>